Dominic E. Warrino
Research Subjects
Dominic E. Warrino has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alok Rathi
BioAgilytix Boston, Boston, Massachusetts, USA
1 shared publication - Chongwoo Yu
US Food and Drug Administration, Silver Spring, Maryland, USA
1 shared publication - David G. Rizzo
AbbVie Inc., North Chicago, Illinois, USA
1 shared publication - Feng Yin
Department of Nonclinical Research, Pyxis Oncology, Inc., 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA
1 shared publication - Honglue Shen
Merck & Co., Inc., Rahway, New Jersey, USA
1 shared publication - Inês Carvalho Santos
Bristol Myers Squibb, Lawrenceville, New Jersey, USA
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (4)
Updated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community
Antibody–drug conjugates (ADCs) represent a rapidly evolving therapeutic modality, combining the selective targeting of monoclonal antibodies with highly potent small molecule payloads. Their inherent structural complexity demands a sophisticated and multi-faceted bioanalytical approach spanning preclinical discovery through late-stage clinical development. This white paper, developed by the ADC Working Group of the AAPS bioanalytical community, comprising over 100 members from industry, contract research organizations (CROs), and regulatory agencies, provides updated recommendations for ADC bioanalysis. Building upon the foundational 2013 AAPS position paper and recent publications governing regulatory frameworks on PK considerations, this work addresses advances in bioanalytical quantitation strategies for total antibody (tAb), conjugated ADC, free (unconjugated) payload, and drug-to antibody ratio (DAR); novel immunogenicity assessment considerations; soluble target interference; critical reagent lifecycle management; payload-specific stability requirements; cross-validation strategies; and regulatory considerations. The recommendations presented herein reflect over a decade of scientific progress and are designed to serve as a comprehensive, empirically validated, and industry aligned bioanalytical framework for contemporary ADC drug development.
- 1 July 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (4)
Open AccessUpdated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community
Antibody–drug conjugates (ADCs) represent a rapidly evolving therapeutic modality, combining the selective targeting of monoclonal antibodies with highly potent small molecule payloads. Their inherent structural complexity demands a sophisticated and multi-faceted bioanalytical approach spanning preclinical discovery through late-stage clinical development. This white paper, developed by the ADC Working Group of the AAPS bioanalytical community, comprising over 100 members from industry, contract research organizations (CROs), and regulatory agencies, provides updated recommendations for ADC bioanalysis. Building upon the foundational 2013 AAPS position paper and recent publications governing regulatory frameworks on PK considerations, this work addresses advances in bioanalytical quantitation strategies for total antibody (tAb), conjugated ADC, free (unconjugated) payload, and drug-to antibody ratio (DAR); novel immunogenicity assessment considerations; soluble target interference; critical reagent lifecycle management; payload-specific stability requirements; cross-validation strategies; and regulatory considerations. The recommendations presented herein reflect over a decade of scientific progress and are designed to serve as a comprehensive, empirically validated, and industry aligned bioanalytical framework for contemporary ADC drug development.